CONCORDIA RX Trademark
Trademark Overview
On Thursday, May 16, 2024, a trademark application was filed for CONCORDIA RX with the United States Patent and Trademark Office. The USPTO has given the CONCORDIA RX trademark a serial number of 98553736. The federal status of this trademark filing is PREVIOUS ACTION/ALLOWANCE COUNT WITHDRAWN as of Thursday, February 19, 2026. This trademark is owned by Concordia Pharmaceuticals Inc., S.à.r.L. The CONCORDIA RX trademark is filed in the Pharmaceutical Products category with the following description:
a full line of pharmaceuticals for the treatment of depression, malaria, benign prostatic hyperplasia, partial seizures in adults with epilepsy, heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
General Information
| Serial Number | 98553736 |
| Word Mark | CONCORDIA RX |
| Filing Date | Thursday, May 16, 2024 |
| Status | 643 - PREVIOUS ACTION/ALLOWANCE COUNT WITHDRAWN |
| Status Date | Thursday, February 19, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | a full line of pharmaceuticals for the treatment of depression, malaria, benign prostatic hyperplasia, partial seizures in adults with epilepsy, heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids) |
| NOT AVAILABLE | "RX" |
| Description of Mark | The mark consists of the stylized wording "CONCORDIA", with the prescription symbol "RX" forming the "R" in "CONCORDIA". |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 16, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | Tuesday, February 28, 2017 |
| First Use In Commerce Date | Tuesday, February 28, 2017 |
Trademark Owner History
| Party Name | Concordia Pharmaceuticals Inc., S.à.r.L |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Luxembourg L-1610
LU |
Trademark Events
| Event Date | Event Description |
| Thursday, May 16, 2024 | NEW APPLICATION ENTERED |
| Monday, November 18, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, November 18, 2024 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Monday, December 2, 2024 | ASSIGNED TO EXAMINER |
| Sunday, December 22, 2024 | NON-FINAL ACTION WRITTEN |
| Sunday, December 22, 2024 | NON-FINAL ACTION E-MAILED |
| Sunday, December 22, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, March 18, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, March 18, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, June 23, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, June 23, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, June 23, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, July 25, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, July 25, 2025 | NON-FINAL ACTION E-MAILED |
| Friday, July 25, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, October 27, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, October 27, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, January 23, 2026 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, January 23, 2026 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, January 23, 2026 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, January 23, 2026 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Friday, January 23, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, January 23, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, January 23, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, January 26, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, February 10, 2026 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Thursday, February 19, 2026 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
